Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placebo
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT02835235
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT02827708
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 472
- Registration Number
- NCT02825251
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, St Helens, United Kingdom
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1355
- Registration Number
- NCT02821052
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3303
- Registration Number
- NCT02779413
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Wonju, Korea, Republic of
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 420
- Registration Number
- NCT02773368
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT02773355
- Locations
- 🇲🇽
Novo Nordisk Investigational Site, Puebla, Mexico
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT02773381
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 543
- Registration Number
- NCT02762578
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Tianjin, China
A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT02754817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath